dementia
Roche Nabs FDA Clearance for Alzheimer's Assays
The cerebrospinal fluid-based immunoassays provide ratios that reflect pathologies of Alzheimer's disease and can aid earlier diagnosis.
CND Life Sciences Closes $4.5M Series Seed 3 Financing Round
The company will use the funding to accelerate commercialization of its Syn-One test for identifying abnormal alpha-synuclein aggregation via skin biopsy.
CND Life Sciences, Beth Israel Ink Licensing Deal for Neurodegenerative Disease Test Technology
The agreement gives CND access to technologies key to CND's skin biopsy-based test for the hallmarks of the synucleinopathy family of neurodegenerative diseases.
Metabolon Partners With Swedish Biofinder 2 Study to Develop Dementia Biomarkers
The company will run metabolomics on cerebrospinal fluid and plasma from the study's baseline collections to identify biomarkers.
Amprion Wins Additional $730K NIH Grant to Validate Parkinson's Disease Test
The recently launched test is designed to detect a-synuclein aggregates to aid in the diagnosis of Parkinson's disease and other brain conditions.